Etigilimab Biosimilar - Research Grade

Human

TIGIT

>1mg/ml

IgG1 - kappa

CHO Cells

Anti-Human TIGIT (4E1.2) In Vivo Antibody - Low Endotoxin (ICH1219), Anti-Mouse TIGIT (1G9) In Vivo Antibody - Low Endotoxin (ICH1220), Tiragolumab Biosimilar - Research Grade (ICH5078), Vibostolimab Biosimilar - Research Grade (ICH5159), Tamgiblimab Biosimilar - Research Grade (ICH5279), Belrestotug Biosimilar - Research Grade (ICH5384), Dargistotug Biosimilar - Research Grade (ICH5465), Domvanalimab Biosimilar - Research Grade (ICH5486), Lancastotug Biosimilar - Research Grade (ICH5623), Ociperlimab Biosimilar - Research Grade (ICH5722), Ralzapastotug Biosimilar - Research Grade (ICH5803), Renvistobart Biosimilar - Research Grade (ICH5816)

https://www.imgt.org/mAb-DB/

ICH3002

Q495A1

Blue ice

This product is a research-grade, unconjugated recombinant analog of the anti-TIGIT antibody etigilimab, supplied for research use only. It is a non-therapeutic biosimilar built around the same human TIGIT target and a human IgG1/kappa framework, and it is not the clinical drug and not intended for human or veterinary use. As a laboratory reagent it is useful for functional characterization of TIGIT-directed biology: measuring binding to recombinant or cell-surface human TIGIT, blocking the TIGIT interaction with its ligands, isotype-matched control experiments, and as a benchmark or reference standard in assay development. It also supports antibody-engineering and ADCC/effector-function studies, epitope-competition work, and preclinical in-vitro screening. The material is offered at research grade with low endotoxin (typically less than 1 EU/mg, with an ultra-low sub-0.5 EU/mg option) and is available in bulk milligram-to-gram quantities suitable for repeated experiments and scale-up. Because it reproduces the target specificity of the originator without therapeutic intent, it lets researchers study TIGIT-axis pharmacology and immune-checkpoint mechanisms in controlled experimental systems. TIGIT (T-cell immunoreceptor with Ig and ITIM domains; UniProt Q495A1) is an inhibitory immune-checkpoint receptor expressed on T cells and natural killer cells, including regulatory T cells, activated and memory CD8 and CD4 T cells, and NK cells. It binds the nectin-family ligands CD155 (PVR) and, with lower affinity, CD112 (nectin-2), competing with the co-stimulatory receptor CD226 (DNAM-1) for CD155. TIGIT engagement delivers inhibitory signals through its cytoplasmic ITIM and ITT-like motifs, dampening T-cell and NK-cell activation, cytokine production, and cytotoxicity, and it can also promote tolerogenic dendritic-cell signaling via CD155. Because tumors and chronic-infection settings exploit this axis to suppress immunity, TIGIT is a prominent target for checkpoint-blockade research aimed at restoring anti-tumor T-cell and NK-cell function, frequently studied alongside the PD-1/PD-L1 pathway.

V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3, T-cell immunoreceptor with Ig and ITIM domains, VSIG9, VSTM3

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks